Abstract 112P
Background
Biliary tract cancers (BTC), including cholangiocarcinomas (CCA) are rare but aggressive cancers primarily affecting patients (pts) >70 years (median age at diagnosis : 72-78 years). However, there has been a rise in the incidence of CCA among younger individuals (<50 years). This study aimed to investigate clinical, genomic and transcriptomic characteristics and outcomes of young-onset BTC/CCA (YOC) pts.
Methods
We identified all consecutive patients with histologically confirmed CCA treated at Gustave Roussy (France) between 2015 and 2021 as part of the ACABI-PRONOBIL multicenter cohort study. Clinical data were extracted from medical records. Genomic data were obtained through in-house or Foundation Medicine® panels. Transcriptomic analyses were performed for 58 pts (13 YOC) at metastatic diagnosis.
Results
Of the 546 pts with CCA, 92 (16.8%) had YOC (median age, 42 years; range, 27-50). Median overall survival (mOS) from 1st line therapy was 22.7 months (mo) (95%CI: 18.3-27.6) for YOC patients vs 19.2 mo (95%CI: 18.0-22.0) for non-YOC patients (p=0.14). Molecular profiling was more often performed for YOC pts (68% vs 55%, p<0.05). Rates of actionable molecular alterations (IDH1/2, BRAF, FGFR2, NTRK, HER2, MSI) and targeted therapies administration did not differ between YOC and non-YOC pts. CDKN2A alterations were less frequent in YOC than in non-YOC pts (12.6% vs 25.2%, p<0.05). Differentially expressed genes between YOC and non-YOC pts with Gene Set Enrichment Analysis were mostly genes involved in immunity and WNT signaling pathways. Table: 112P
| Genomic characteristics | Age <=50 n=92 | age>50 n=454[BA1] | |||
| n | % | n | % | ||
| Molecular profile available | No | 29 | 32% | 204 | 45% |
| Yes | 63 | 68% | 250 | 55% | |
| Actionable alteration | No | 41 | 65% | 141 | 56% |
| Yes | 22 | 35% | 109 | 44% | |
| Main actionable alterations | No alteration | 11 | 17% | 43 | 17% |
| Mutation IDH1/2 | 8 | 13% | 40 | 16% | |
| Fusion FGFR 1-4 | 8 | 13% | 21 | 8% | |
| Amplification HER2 | 3 | 5% | 15 | 6% | |
| Mutation BRAF V600E | 0 | 0% | 10 | 4% | |
| EGFR | 2 | 3% | 7 | 3% | |
| Fusion NTRK | 6 | 10% | 11 | 4% | |
| Mutation KRAS G12C | 1 | 2% | 3 | 1% | |
| Other relevant alterations | KRAS | 16 | 25% | 40 | 16% |
| TP53 | 25 | 40% | 91 | 36% | |
| CDKN2A/B | 8 | 13% | 63 | 25% | |
| MMR status (n=199) | dMMR/MSI | 0 | 0% | 11 | 7% |
| pMMR/MSS | 47 | 100% | 141 | 93% | |
| Targeted therapies administration | No | 41 | 65% | 141 | 56% |
| Yes | 22 | 35% | 109 | 44% |
Conclusions
Although tending to have a more advanced disease at diagnosis, YOC patients had OS similar to that of non-YOC pts, and no more actionable molecular alterations. Our findings suggest that the biological mechanisms driving CCA in YOC patients may be different from those in older patients and warrant further investigation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Gercor.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
720TiP - Phase I, open-label, first-in-human (FIH) study of JZP815 in advanced or metastatic solid tumors harboring mitogen-activated protein kinase (MAPK) alterations
Presenter: Abdul-Rafeh Naqash
Session: Poster session 17
722TiP - CLAUDIO-01: A multicentric phase I/II trial to evaluate the safety and efficacy of SOT102 as monotherapy and in combination with standard of care (SoC) in patients with gastric, gastroesophageal junction(GEJ), and pancreatic adenocarcinoma
Presenter: Radka Obermannova
Session: Poster session 17
732P - Efficacy and safety of high-dose chemotherapy as second or subsequent salvage therapy in relapsed or refractory germ cell cancer patients: A multicentric analysis
Presenter: Christoph Seidel
Session: Poster session 17
733P - Testicular cancer: Trends in incidence and demographics from 23,214 cases in California from 2000-2020
Presenter: David Benjamin
Session: Poster session 17
734P - Primary retroperitoneal germ-cell tumours (pR-GCT): Evaluation of treatment outcomes of an international collaboration (PRIMERE study-IGG05)
Presenter: Patrizia Giannatempo
Session: Poster session 17